| 14.9 -0.36 (-2.36%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 22.2  |
1-year : | 25.31 |
| Resists | First : | 19.01 |
Second : | 21.67 |
| Pivot price | 17.16 |
|||
| Supports | First : | 14.72 |
Second : | 12.24 |
| MAs | MA(5) : | 15.77 |
MA(20) : | 17.5 |
| MA(100) : | 22.89 |
MA(250) : | 18.19  |
|
| MACD | MACD : | -1.3 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 1.4 |
D(3) : | 1.4 |
| RSI | RSI(14): 26.8 |
|||
| 52-week | High : | 33.13 | Low : | 9.18 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CVRX ] has closed above bottom band by 1.6%. Bollinger Bands are 19.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.67 - 15.82 | 15.82 - 15.91 |
| Low: | 14.41 - 14.6 | 14.6 - 14.72 |
| Close: | 14.68 - 14.99 | 14.99 - 15.18 |
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Fri, 19 Apr 2024
CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits - Yahoo Finance
Tue, 16 Apr 2024
CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024 - GlobeNewswire
Tue, 16 Apr 2024
CVRx has more data supporting long-term benefits of Barostim - Mass Device
Mon, 15 Apr 2024
CVRx reports sustained heart failure therapy benefits By Investing.com - Investing.com
Mon, 15 Apr 2024
CVRx announces availability of additional data supporting long-term benefits of Barostim - Marketscreener.com
Mon, 25 Mar 2024
CVRx's Barostim Neo Neuromodulation System, US - Medical Device Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 21 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 9.8 (%) |
| Held by Institutions | 77.6 (%) |
| Shares Short | 831 (K) |
| Shares Short P.Month | 671 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.64 |
| Profit Margin | -104.9 % |
| Operating Margin | -85.5 % |
| Return on Assets (ttm) | -22.5 % |
| Return on Equity (ttm) | -44.6 % |
| Qtrly Rev. Growth | 57.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.87 |
| EBITDA (p.s.) | -2.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -7.49 |
| PEG Ratio | 0 |
| Price to Book value | 4.09 |
| Price to Sales | 7.93 |
| Price to Cash Flow | -8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|